Sistema de Salut de Catalunya
Institut Català de la Salut
[Yu HA] Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. [Yang JC] Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan. [Hayashi H] Department of Medical Oncology, Kindai University, Osaka, Japan. [Goto Y] Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Reck M] Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
Vall d'Hebron Barcelona Hospital Campus
2023-09-07T10:39:43Z
2023-09-07T10:39:43Z
2023-06
Antibody–drug conjugate; Non-small-cell lung cancer; Patritumab deruxtecan
Conjugat anticossos-fàrmac; Càncer de pulmó de cèl·lules no petites; Patritumab deruxtecan
Conjugado anticuerpo-fármaco; Cáncer de pulmón de células no pequeñas; Patritumab deruxtecan
Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients. Patritumab deruxtecan (HER3-DXd) is an investigational, potential first-in-class, HER3-directed antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. In an ongoing phase I study, HER3-DXd demonstrated promising antitumor activity and a tolerable safety profile in patients with EGFR-mutated NSCLC, with or without identified EGFR TKI resistance mechanisms, providing proof of concept of HER3-DXd. HERTHENA-Lung01 is a global, registrational, phase II trial further evaluating HER3-DXd in previously treated advanced EGFR-mutated NSCLC.
Article
Published version
English
Anomalies cromosòmiques; Pulmons - Càncer - Tractament; Immunoglobulines - Ús terapèutic; DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates; PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados; FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
Future Medicine
Future Oncology;19(19)
http://dx.doi.org/10.2217/fon-2022-1250
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
